Australian manufacturing facility clears key regulatory hurdle
OncoSil Medical (ASX: OSL) has announced that Cyclotek, its contract manufacturer, has received ISO 13485 certification for OncoSil Medical’s Macquarie Park facility in Sydney. The certification represents a concrete regulatory milestone in the company’s pathway toward local production of the OncoSil™ device, with the company aiming to commence production at the site by the end of 2Q FY27, subject to applicable regulatory review and approval processes.
This is one step in a multi-step process. The next regulatory requirement is to add the Macquarie Park site as a critical subcontractor to OncoSil Medical’s existing Notified Body (NB) before production can begin.
When big ASX news breaks, our subscribers know first
What ISO 13485 certification means and why it matters for investors
ISO 13485 is an internationally recognised standard that specifies quality management system (QMS) requirements for organisations involved in the design, production, and manufacture of medical devices. In practical terms, Cyclotek’s certification confirms that its QMS meets this international benchmark, demonstrating the operational readiness of the Macquarie Park site.
Importantly, ISO 13485 is a prerequisite rather than an end goal. It enables the next regulatory step, which involves the Notified Body adding the Macquarie Park facility to OncoSil Medical’s existing certificate. Only once that process is complete can commercial production begin.
For investors, the certification clears a meaningful regulatory gate and supports the company’s stated target of commencing OncoSil™ production at Macquarie Park by the end of 2Q FY27, subject to applicable regulatory review and approval processes.
The Macquarie Park facility: building a scalable, capital-efficient manufacturing platform
The Macquarie Park facility has been designed to serve as a long-term manufacturing platform, combining supply chain advantages with a capital-efficient operating model. Key features of the facility include:
- Combines Cyclotek’s existing infrastructure with OncoSil-owned manufacturing equipment and the company’s proprietary manufacturing process
- Designed for scalable production to support increasing global demand for the OncoSil™ device
- Capital intensity of less than 5% at full capacity
- Expected to provide greater control over product quality and supply chain resilience
- Increased production volumes and manufacturing efficiencies are expected to support gross margin improvement over time
Nigel Lange, CEO & Managing Director
“Macquarie Park is an important part of our strategy to build a scalable and capital-efficient manufacturing platform to support our growing global commercial activities. As we scale, we expect the facility to provide greater control over product quality and our supply chain, while driving manufacturing efficiencies that have the potential to significantly improve gross margins over time.”
The table below summarises the regulatory pathway steps toward production at Macquarie Park:
| Step | Milestone | Status |
|---|---|---|
| 1 | Cyclotek achieves ISO 13485 certification | Complete |
| 2 | Add Macquarie Park as critical subcontractor to OncoSil Medical’s Notified Body (NB) | In progress |
| 3 | NB adds Macquarie Park to OncoSil Medical’s existing certificate | Pending |
| 4 | Commence OncoSil™ production at Macquarie Park | Target: end of 2Q FY27 (subject to regulatory review and approval) |
OncoSil Medical’s global commercial context
The Macquarie Park facility is being built to support an already-active global commercial operation. Key points from the company’s background include:
- OncoSil™ is currently approved for sale in 30+ countries, including the EU, UK, US, Australia, Saudi Arabia, Türkiye, and Israel
- Commercial treatments have already been undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, and the UK
- OncoSil™ targets unresectable locally advanced pancreatic cancer (LAPC) and distal cholangiocarcinoma (dCCA)
- The device has been designated as a Breakthrough Device in both Europe and the United States
- Pancreatic cancer alone accounts for approximately 500,000 new cases detected annually, according to the International Agency for Research on Cancer (IARC)
TRIPP-FFX trial results published in June 2026 showed an 82.2% local disease control rate and median overall survival of 18.3 months in the OncoSil plus FOLFIRINOX arm, providing the clinical evidence base underpinning the label expansion submission and the growing global demand the Macquarie Park facility is designed to serve.
The Macquarie Park facility, once operational, is intended to support this existing and growing global demand with a scalable and capital-efficient production model.
For investors tracking the broader FY27 catalyst pipeline alongside the Macquarie Park certification milestone, our detailed coverage of the $5.6 million institutional raise outlines how management has allocated capital across the US commercial launch, Australian manufacturing, and European regulatory filings expected through FY27.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to receive the next market-moving update the moment it breaks.